CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 414 filers reported holding CRISPR THERAPEUTICS AG in Q4 2020. The put-call ratio across all filers is 1.10 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $32,590 | +12.1% | 718 | +38.6% | 0.02% | +14.3% |
| Q2 2023 | $29,081 | +24.1% | 518 | 0.0% | 0.01% | +16.7% |
| Q1 2023 | $23,429 | +11.3% | 518 | 0.0% | 0.01% | 0.0% |
| Q4 2022 | $21,057 | -38.1% | 518 | 0.0% | 0.01% | -40.0% |
| Q3 2022 | $34,000 | +9.7% | 518 | +0.4% | 0.02% | +5.3% |
| Q2 2022 | $31,000 | -42.6% | 516 | -39.5% | 0.02% | -29.6% |
| Q1 2022 | $54,000 | +25.6% | 853 | +51.0% | 0.03% | +35.0% |
| Q4 2021 | $43,000 | +34.4% | 565 | +97.6% | 0.02% | 0.0% |
| Q3 2021 | $32,000 | -15.8% | 286 | +21.7% | 0.02% | -13.0% |
| Q2 2021 | $38,000 | +31.0% | 235 | 0.0% | 0.02% | +9.5% |
| Q1 2021 | $29,000 | -86.3% | 235 | -83.0% | 0.02% | -88.0% |
| Q4 2020 | $212,000 | +53.6% | 1,385 | -15.8% | 0.18% | +28.7% |
| Q3 2020 | $138,000 | – | 1,644 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $32,581,000 | 55.55% |
| NEA Management Company, LLC | 1,590,002 | $103,907,000 | 5.19% |
| ARK Investment Management | 8,237,122 | $538,296,000 | 3.75% |
| Nikko Asset Management Americas, Inc. | 4,262,736 | $277,078,000 | 3.54% |
| CLOUGH CAPITAL PARTNERS L P | 414,767 | $27,105,000 | 2.89% |
| Integral Health Asset Management, LLC | 220,000 | $14,377,000 | 2.79% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,268,000 | 2.48% |
| HC Advisors, LLC | 53,944 | $3,525,000 | 2.43% |
| Green Alpha Advisors, LLC | 27,466 | $1,795,000 | 1.52% |
| EFG Asset Management (North America) Corp. | 84,356 | $5,516,000 | 1.28% |